ADVANCES IN THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
DOI:
https://doi.org/10.36557/2674-8169.2026v8n1p505-518Keywords:
tratamento, Trombose, púrpura trombocitopênica idiopáticaAbstract
Introduction: Thrombotic Thrombocytopenic Purpura (TTP) is a severe thrombotic microangiopathy driven by ADAMTS13 deficiency and subsequent microthrombosis. Despite standard therapies, the emergence of caplacizumab, a von Willebrand factor inhibitor, represents an advancement in the treatment of acquired TTP (aTTP). Objective: To identify how the addition of Caplacizumab influences the main clinical and laboratory outcomes in patients with acquired TTP. Methods: This is an Integrative Literature Review that used specific descriptors related to acquired TTP and Caplacizumab. Inclusion criteria were defined as English/Portuguese language, presence of descriptors in the title, a five-year time frame, and availability of full articles; exclusion criteria included duplicates and studies not relevant to the research question. The initial search identified 218 studies, of which 15 met all criteria and formed the final sample. Conclusion: Caplacizumab stands out as an essential therapy in acquired TTP, accelerating recovery and reducing complications. Its consistent efficacy is reshaping treatment, making it safer and less invasive.
Keywords: Thrombosis, Thrombocytopenic Purpura, Treatment.
Downloads
References
AL-MASHDALI, Abdulrahman F. et al. Caplacizumab for pediatric immune thrombotic thrombocytopenic Purpura: A scoping review of current evidence. Blood reviews, v. 74, n. 101326, p. 101326, 2025.
COPPO, Paul et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood, v. 137, n. 6, p. 733–742, 2021.
DANE, Kathryn; CHATURVEDI, Shruti. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology, v. 2018, n. 1, p. 539–547, 2018.
DUTT, Tina et al. Real-world experience with caplacizumab in the management of acute TTP. Blood, v. 137, n. 13, p. 1731–1740, 2021.
ELVERDI, Tugrul; ESKAZAN, Ahmet Emre. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. Drug design, development and therapy, v. 13, p. 1251–1258, 2019.
KNOEBL, Paul et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of thrombosis and haemostasis: JTH, v. 18, n. 2, p. 479–484, 2020.
KÜHNE, Lucas et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange. Blood, v. 144, n. 14, p. 1486–1495, 2024.
PEYVANDI, F. et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis: JTH, v. 15, n. 7, p. 1448–1452, 2017.
PEYVANDI, Flora et al. Caplacizumab for acquired thrombotic thrombocytopenic Purpura. The New England journal of medicine, v. 374, n. 6, p. 511–522, 2016.
PEYVANDI, Flora et al. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood advances, v. 5, n. 8, p. 2137–2141, 2021.
SCULLY, Marie et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura. The New England journal of medicine, v. 380, n. 4, p. 335–346, 2019.
SCULLY, Marie et al. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. Journal of thrombosis and haemostasis: JTH, v. 20, n. 12, p. 2810–2822, 2022.
TAYLOR, Alice et al. Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience. Blood advances, v. 8, n. 17, p. 4563–4567, 2024.
VÖLKER, Linus A. et al. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. Journal of thrombosis and haemostasis: JTH, v. 18, n. 11, p. 3061–3066, 2020a.
VÖLKER, Linus A. et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood advances, v. 4, n. 13, p. 3085–3092, 2020b.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Henrique Jorge Rebouças Júnior, Gabriel Antonio Mouta Gomes , Gabriel dos Santos Medeiros, Livia Layanne Lopes Fernandes Rodrigues , Felipe Modesto Almeida Rebouças, Nadson Lopes Nunes , Karem Gabrielle Penha Carvalho , Mariana Moura de Farias, Yan Carlos de Sousa Diniz , Thayná Rakel Quirino Lucena , Adson Justino da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
